PDCD1 and asthma: Treatment with inhaled corticosteroids and long-acting beta-2 agonists improved the symptoms of asthma.[3] On the other hand, Ogawa et al reported pembrolizumab-induced fatal CD8+ infiltrated asthma-like bronchitis in a patient with NSCLC.[4] Mitropoulou et al reported 2 cases of severe bronchitis attributable to nivolumab with or without ipilimumab in patients with melanoma and NSCLC.[5] Airway diseases such as asthma and bronchitis have been recognized as a new pattern of irAE; hence, asthma-like symptoms should be monitored when an anti-PD-1 antibody is administered.